Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:CASNumber |
2228327-56-6
|
| gptkbp:clinicalTrialPhase |
Phase 1/1b
|
| gptkbp:developedBy |
gptkb:Surface_Oncology
|
| gptkbp:effect |
enhances anti-tumor immune response
|
| https://www.w3.org/2000/01/rdf-schema#label |
SRF617
|
| gptkbp:intendedUse |
immunotherapy
|
| gptkbp:mechanismOfAction |
CD39 inhibition
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
investigational
|
| gptkbp:studiedBy |
solid tumors
hematologic malignancies |
| gptkbp:target |
gptkb:CD39
|
| gptkbp:bfsParent |
gptkb:Surface_Oncology
|
| gptkbp:bfsLayer |
7
|